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Sixteen patients with stable angina pectoris were studied
in a double blind crossover manner utilizing treadmill
exercise testing with the direct measurement of total
body oxygen uptake, 1 and 24 hours after application
of a 20 cm2 transdermal nitroglycerin system and iden-
tical placebo. Testing was performed after a 3 day lead-
in period of treatment with either an active patch or
placebo. Points of analysis were peak angina and the
submaximal work lo~d occurring at 4 minutes of exer-
cise. Nostatistically significantdifferenceswere observed
between nitroglycerin and placebo treatment in any of
the rest hemodynamic or peak angina variables at 1 or
24 hours. A significant increase in the rate-pressure
It has been suggested that transdermal nitroglycerin systems
offer 24 hour prophylactic relief from exertional angina
pectoris (1,2). The basis for this extended therapeutic effect
was inferred from studies documenting constant plasma ni-
troglycerin levels 24 hours after transdermal application and
from preliminary studies in patients with angina pectoris
(3-6). However, recent controlled studies (7-10) have
produced conflicting results as to the efficacy of transdermal
nitroglycerin systems in patients with angina. Thompson (7)
observed significant increases in treadmill exercise time 2
and 26 hours after the application of individually titrated
transdermal nitroglycerin patches. In contrast, other inves-
tigators (8,9) were unable to document significant changes
in exercise capacity 24 hours after the application of trans-
dermal nitroglycerin, although increases in exercise time
were observed at intervals up to 8 hours. The present in-
vestigation supports the contention that once daily appli-
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product at the submaximal work load was observed 1
hour after transdermal nitroglycerin relative to placebo
application. However, no significantdifferences were ob-
served in any of the other measured variables at the
submaximal work load, 1 or 24 hours after nitroglycerin
application.
The once daily application of a 20 cnr' transdermal
nitroglycerin system was ineffective in altering the ex-
ercise capacity of patients with angina pectoris. The lack
of efficacy at 1 hour appears to be due to inadequate
nitroglycerin blood levels; at 24 hours it may be due to
tolerance.
(J Am Coil Cardiol1985;5:1220-3)
cation of transdermal nitroglycerin systems is ineffective in
altering the exercise capacity of patients with stable angina
pectoris.
Methods
Patients. Sixteen male volunteers ranging from 42 to
70 years of age and with exertional angina pectoris asso-
ciated with abnormal ST segment depression were included
in the study. Twelve patients had angiographically docu-
mented coronary artery disease; the remaining four had a
history of typical exertional angina and 2 mm of exercise-
induced ST segment depression. Eleven patients had a pre-
vious myocardial infarction. During the study, eight patients
were taking a beta-receptor blocking agent; three were tak-
ing propranolol, three were taking atenolol and two were
taking nadolol. In addition, one patient taking propranolol
was also taking nifedipine. All patients were known to re-
spond to nitrates and had their regular nitrate therapy dis-
continued 12 hours before the baseline test. All rights and
privileges were honored in accordance with established Hu-
man Subjects Protocol and informed written consent was
obtained. The study was approved by the Human Subjects
Committee of the University of California at San Diego.
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Study design. The study design was a randomized dou-
ble blind, two period crossover. Exercise tests were per-
formed at baseline and I and 24 hours after application of
transdermal nitroglycerin or placebo. Each patient applied
to the anterior chest wall a 20 ern? transdermal system that
was designed to deliver 10 mg of nitroglycerin over 24
hours. Because of the blinded design, dosage could not be
titrated. A 3 day lead-in period was initiated before both
the treatment and the placebo exercise tests.
Testing procedures. The patients were exercised on a
calibrated motor-driven treadmill. After the baseline test,
the patients underwent exercise testing at the same time of
day 1 week later. The baseline test was given to evaluate
their current clinical condition and allow them to become
familiar with the procedure. All testing was done in the
fasting state, with no food eaten for at least 3 hours before
testing. Individualized protocols were designed to provide
small increments in work that would allow the patients suf-
ficient time on the treadmill before reaching a symptom-
limited end point. These protocols conformed to guidelines
for testing patients with stable angina pectoris outlined by
Redwood et al. (11). The patients' subjective perception of
anginal pain was evaluated using the Borg scale (12). The
patients were taught the proper hand signals to indicate the
severity of anginal pain.
Two points of analysis were used in the study: 1) peak
angina, corresponding to the level of pain at which the
patient would normally stop exercise to take sublingual ni-
troglycerin; and 2) the submaximal work load that occurred
at 4 minutes of exercise. The submaximal work load was
included as an objective measure of the medication's ef-
fectiveness since it provided a standard amount of external
work at which the measured variables could be compared.
The direct measurement of total body oxygen uptake was
included in the study. Patients breathed through a Koegel
valve, and expired gas was collected continuously in mete-
orologic balloons each minute during the exercise test (13, 14).
Mixed expired oxygen and carbon dioxide levels were mea-
sured with an Applied Electrochemistry S-3A oxygen ana-
lyzer and a Gould Godart Mark IV capnograph. Expired
volumes were determined by evacuating the balloons through
a dry gas meter calibrated with a Tissot spirometer at a fixed
flow rate. The peak oxygen uptake was measured from the
last 30 second sample obtained before the symptom-limited
end point.
Analysis of data. Before an exercise test, each patient
was carefully prepared using the Dalhousie square, and a
15 lead electrocardiogram was acquired using the placement
of exercise electrodes prepared by University of California-
San Diego (15). Computerized acquisition, processing and
analysis of the electrocardiogram were performed as pre-
viously outlined (16). The ST segment displacement 60 ms
after the J junction (ST60) in the lead with the greatest ST
depression at peak exercise during the baseline study was
used as an objective measure of myocardial ischemia. Rest
and exercise heart rates were averaged from three consec-
utive electrocardiographic QRS complexes. Blood pressure
was recorded for each patient using a clinical sphygmo-
manometer. The reproducibility of all of our methods has
recently been presented (17).
Statistics. Grizzle's parametric method for a two period
crossover study was applied to the data (18). Preliminary
tests revealed no sequence effect for any of the; measured
variables presented. Thus, analysis of variance (ANqVM
was performed and the medication effect examined at the
0.05 level of significance. In addition, separate analyses
controlling for a possible beta-receptor blocking effect were
performed on the measured variables using parametric
techniques.
Results
Rest hemodynamic variables. Mean (± 1 SD) stand-
ing and supine rest heart rates and blood pressures at 1 and
24 hours after transdermal application of nitroglycerin and
placebo are presented in Table 1. No statistically significant
differences were observed at either time period between
application of transdermal nitroglycerin and placebo for any
of the measured rest hemodynamic variables.
One hour measurements (Table 1). At 1 hour after
application, the rate-pressure product at the submaximal
work load was significantly increased during transdermal
nitroglycerin when compared with placebo application (mean
increase 11 mm Hg; p < 0.05). There were no statistically
significant differences at 1 hour between transdermal nitro-
glycerin and placebo for any of the other measured variables
at a submaximal work load or peak angina.
Twenty-four hour measurements (Table 1). At 24 hours
after application of transdermal nitroglycerin or placebo,
there were no statistically significant differences between
the two treatments for any of the measured variables at a
submaximal work load or peak angina.
Beta-receptor blocking effect. Separate analysis con-
trolling for a beta-receptor blocking effect revealed signif-
icantly more ST segment depression at peak angina during
transdermal nitroglycerin than placebo application at 24 hours
in the group of patients taking a beta-receptor blocking agent
(nitroglycerin -0.19 mm versus placebo -0.15 mm). In
addition, at 24 hours this group also had greater rest supine
systolic and diastolic blood pressures during nitroglycerin
than during placebo application (mean increase 8 mm Hg
systolic, 6 mm Hg diastolic; p < 0.05).
Subjective effects. There was no consistent pattern in
the response of the patients to the active patches in regard
to relief from angina or side effects.
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Table 1. Mean (±SD) of the Rest and Exercise Hemodynamic and ST Segment Variables I and 24 Hours After Application of
Transdermal Nitroglycerin or Placebo.
I Hour 24 Hours
Transderm Placebo Transderm Placebo
Rest
Standing
Heart rate (beats/min) 71 (13) 68 (11) 71 (13) 72 (14)
Systolic blood pressure (mm Hg) 127 (13) 125 (10) 130 (13) 127 (15)
Diastolic blood pressure (mm Hg) 89 (11) 83 (7) 85 (9) 83 (8)
Supine
Heart rate (beats/min) 62 (II) 59 (9) 63 (11) 63 (9)
Systolic blood pressure (mm Hg) 128 (17) 126 (15) 129 (13) 125 (17)
Diastolic blood pressure (mm Hg) 83 (12) 79 (8) 85 (8) 81 (12)
Submaximal exercise
Heart rate (beats/min) 92 (II) 90 (II) 92 (12) 92 (11)
Rate-pressure product ( x 100) 135 (27) 124 (24)* 134 (24) 133 (25)
ST segment depression (mV) -0.06 (0.11) -0.05 (0.10) -0.06 (0.11) -0.05 (0.13)
Treadmill time (seconds) 240 (0) 240 (0) 240 (0) 240 (0)
Measured V02 (mllkg per min) 14.2 (1.8) 13.6 (1.5) 13.5 (1.6) 13.6 (1.9)
Peak angina
Heart rate (beats/min) 119 (24) 117 (26) 119 (27) 121 (28)
Rate-pressure product ( x 100) 201 (60) 194 (58) 215 (63) 212 (75)
ST segment depression (mm) -0.21 (0.09) -0.21 (0.14) -0.22 (0.12) -0.20 (0.13)
Treadmill time (seconds) 529 (83) 530 (102) 525 (103) 550 (III)
Measured V02 (ml/kg per min) 22.0 (6.4) 21.7 (5.7) 22.2 (6.1) 22.1 (6.1)
*p < 0.05 between transdermal nitroglycerin (Transderm) and placebo. V02 = oxygen consumption.
Discussion
A chronically administered, once daily application of 20
crrr' transdermal nitroglycerin was ineffective in altering the
exercise capacity in our patients with angina pectoris. A
combination of factors appear to be responsible for the re-
sults obtained in this study. In previous investigations (7,8)
demonstrating an increase in exercise capacity with trans-
dermal nitroglycerin, a titration period was initiated before
the study to determine the maximally tolerated dosage, This
was not done in our study, In addition, the timing of the
initial test, 1 hour after application of the transdermal sys-
tem, may have been too early to detect significant changes
in exercise capacity because of inadequate blood nitroglyc-
erin levels (3,4).
Tolerance. Twenty-four hours after transdermal appli-
cation, blood nitroglycerin concentrations have been ob-
served to be similar to concentrations obtained' at 2 and 8
hours (3,4,9). However, changes in exercise capacity re-
corded 2 and 8 hours after transdermal application did not
persist up to 24 hours (8,9). Although blood nitroglycerin
levels at any time period after transdermal application are
lower than those observed during oral nitrate therapy (19),
the lack of effect we observed at 24 hours may be partly
due to a nitrate tolerance acquired during the 3 day lead-in
period. Investigators (20-23) have repeatedly documented
the development of tolerance to organic nitrates given chron-
ically. Parker et al. (22) observed tolerance to the hemo-
dynamic effects of nitrates to occur within 48 hours after
initiating therapy.
Submaximal exercise findings. Granted the subjective
nature of peak exercise capacity in patients with angina, we
were-unable to demonstrate any positive effects of trans-
dermal nitroglycerin at a submaximal work load at which
reductions in myocardial oxygen supply and demand were
hypothesized to occur. In fact, we observed an increase in
the rate-pressure product during nitroglycerin compared with
placebo application at I hour.
Beta-receptor blocking effect. The concomitant use of
a beta-receptor blocking agent by 8 of our 16 subjects might
havedecreased the sensitivity of detecting a significant ef-
fect after transdermal application. However, all the patients
wer~ carefully screened before the study so that in each
case, exercise tolerance was limited by angina. In addition,
separate analysis of the data controlling for a possible beta-
receptor blocking effect revealed no differences between the
response of patients who were or were not taking a beta-
receptor blocking agent.
Clinical implications. Our results are in agreement with
those pf other investigators (&,9) who observed the inef-
fectiveness of transdermal nitroglycerin systems in altering
the exercise capacity of patients with stable angina pectoris.
Furthermore, we found no evidence of reduced myocardial
oxygen supply or demand at a standard submaximal work
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load at I or 24 hours after application of a 20 crrr' trans-
dermal nitroglycerin system. Future studies should consider
interrupted administration to lessen tolerance and titration
of the dose until a decrease in blood pressure at rest occurs.
Addendum
Two recent publications regarding this subject should be
noted: Crean et al. (24), in a similar study, failed to find
an effect at 2 and 4 hours after patch administration. Abrams
(25) has further described his explanation for the nitropatch
controversy.
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